At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET
Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs. $19.4M a year ago), with EPS of -$0.24 beating the -$0.38 consensus. The company highlighted FDA feedback on a potential Phase 3 path for fasedienol in social anxiety disorder, but cash runway is limited to about one year, raising financing risk.
- Net loss narrowed to $10.7M from $19.4M YoY, driven by lower R&D spend ($6.6M vs $15.9M).
- EPS of -$0.24 beat consensus of -$0.38 (36.8% surprise).
- Cash, equivalents, and marketable securities totaled $20.0M as of Sep 30, 2026, expected to fund operations into 2027 but not beyond one year.
- FDA provided constructive feedback on a potential Phase 3 study of fasedienol in social anxiety disorder, including use of LSAS as primary endpoint.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access